{"id":2498,"date":"2024-01-04T18:44:38","date_gmt":"2024-01-04T23:44:38","guid":{"rendered":"https:\/\/cqdm.org\/en\/news-and-events\/cqdm-welcomes-3-new-network-members\/"},"modified":"2024-09-25T16:24:32","modified_gmt":"2024-09-25T20:24:32","slug":"cqdm-welcomes-3-new-network-members","status":"publish","type":"post","link":"https:\/\/cqdm.org\/en\/news-and-events\/cqdm-welcomes-3-new-network-members\/","title":{"rendered":"CQDM welcomes 3 new &#8221;Network&#8221; Members."},"content":{"rendered":"\n<figure class=\"wp-block-image\"><a href=\"https:\/\/cqdm.org\/wp-content\/uploads\/2024\/01\/nouveaux-membres-EN.jpg\"><img decoding=\"async\" src=\"https:\/\/cqdm.org\/wp-content\/uploads\/2024\/01\/nouveaux-membres-EN-300x169.jpg\" alt=\"\" class=\"wp-image-12287\" title=\"\"><\/a><\/figure>\n\n\n\n<p><strong>CQDM. We connect.<\/strong><br>CQDM welcomes 3 new &#8221;Network&#8221; Members: NanoBrand from Montreal, Two-Photon Research, also from Montreal and BrevisRefero Corporation from Toronto.<br>We invite you to learn more about these 3 new \u201cNetwork\u201d Members as well as the advantages related to this type of CQDM membership via this link:<br><a href=\"https:\/\/cqdm.orgcqdm-membres-du-consortium-biopharmaceutique\/\">https:\/\/cqdm.orgcqdm-membres-du-consortium-biopharmaceutique\/<\/a><br>The &#8221;Network&#8221; membership is accessible and entitles you to several advantages which will facilitate your networking, your contacts and your search for financing, while consolidating your visibility and your impact in the biopharma innovation ecosystem. Don\u2019t hesitate to become a \u201cNetwork\u201d Member too!<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CQDM. We connect.CQDM welcomes 3 new &#8221;Network&#8221; Members: NanoBrand from Montreal, Two-Photon Research, also from Montreal and BrevisRefero Corporation from Toronto.We invite you to learn more about these 3 new \u201cNetwork\u201d Members as well as the advantages related to this type of CQDM membership via this link:https:\/\/cqdm.orgcqdm-membres-du-consortium-biopharmaceutique\/The &#8221;Network&#8221; membership is accessible and entitles you to&hellip;<\/p>\n","protected":false},"author":2,"featured_media":1652,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2498","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-our-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/2498","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/comments?post=2498"}],"version-history":[{"count":2,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/2498\/revisions"}],"predecessor-version":[{"id":4134,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/2498\/revisions\/4134"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media\/1652"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=2498"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/categories?post=2498"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/tags?post=2498"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}